Related references
Note: Only part of the references are listed.Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients
Peilu Wang et al.
CLINICAL CANCER RESEARCH (2016)
Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers
D. Fumagalli et al.
ANNALS OF ONCOLOGY (2016)
ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling
Luca Gelsomino et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Molecular Pathways: Targeting Steroid Receptor Coactivators in Cancer
David M. Lonard et al.
CLINICAL CANCER RESEARCH (2016)
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer
Charlotte Fribbens et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Jill M. Spoerke et al.
NATURE COMMUNICATIONS (2016)
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER plus breast cancer
James D. Joseph et al.
ELIFE (2016)
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial
Sarat Chandarlapaty et al.
JAMA ONCOLOGY (2016)
RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models
Fiona Garner et al.
ANTI-CANCER DRUGS (2015)
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer
Suzanne E. Wardell et al.
CLINICAL CANCER RESEARCH (2015)
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
Andiliy Lai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
Gaia Schiavon et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
Rinath Jeselsohn et al.
CLINICAL CANCER RESEARCH (2014)
The renaissance of endocrine therapy in breast cancer
Nicole Williams et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers
Jamunarani Veeraraghavan et al.
NATURE COMMUNICATIONS (2014)
D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
Keren Merenbakh-Lamin et al.
CANCER RESEARCH (2013)
Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease
Suzanne E. Wardell et al.
CLINICAL CANCER RESEARCH (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
Liquid biopsy: monitoring cancer-genetics in the blood
Emily Crowley et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
Shunqiang Li et al.
CELL REPORTS (2013)
Prognostic Value of Estrogen Receptor α and Progesterone Receptor Conversion in Distant Breast Cancer Metastases
Laurien D. C. Hoefnagel et al.
CANCER (2012)
Genetic heterogeneity and cancer drug resistance
Nicholas C. Turner et al.
LANCET ONCOLOGY (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Growth factor stimulation induces a distinct ERα cistrome underlying breast cancer endocrine resistance
Mathieu Lupien et al.
GENES & DEVELOPMENT (2010)
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2009)
NFκB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses
Kendall W. Nettles et al.
NATURE CHEMICAL BIOLOGY (2008)
Genome-wide analysis of estrogen receptor binding sites
Jason S. Carroll et al.
NATURE GENETICS (2006)
High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene
MI Torres-Arzayus et al.
CANCER CELL (2004)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)